WHY: Spearheaded pivot from failed clinical developer of cancer drugs to being a full-time drug contract manufacturer, more than tripling size of firm since joining in 2020.
BY THE NUMBERS: OC’s second-largest drugmaker with 350 employees. Sales expected to jump 24% this fiscal year to $148.4 million, up from $60 million in 2020. Share price (Nasdaq: CDMO) has nearly tripled since Green’s arrival to a market cap approaching $1 billion as of last week. $75 million expansion project in Costa Mesa, and significant upgrades to main campus in Tustin. Today counts 213,000 square feet across two campuses.
FUTURE PLANS: The OC expansion to its operations has set the company up to reach $400 million in annual sales.
IN THEIR WORDS: “The company’s grown 250% [since 2020]. I’ve doubled the size of the workforce. We’ve spent about $180 million on new equipment and capabilities. We made it profitable. It’s the best job in the world in the best location.”